Home

Impact of COVID-19 Response on Hepatitis Prevention Care and Treatment: Results From Global Survey of Providers and Program Managers

In this month's "Innovations in Hepatitis Elimination" author interview, Dr. Ward will review key findings from the Coalition's global survey of hepatitis providers and program managers on the impact of COVID-19. We will also hear from some of the survey respondents who will describe their experience in delivering hepatitis services during the pandemic, including the challenges they faced and the mitigation strategies they found effective in maintaining access to care for their patients.

325
million
people affected worldwide by hepatitis in 2018
21
countries
account for 64% of the burden
7%
of 71 million people
with chronic hepatitis C have access to treatment

Country profiles

Select a country to see key HBV and HCV related data or check out the data dashboard homepage

Evidence base

The evidence base was developed using rigorous review methods for the identification and quality assessment of eligible systematic reviews, guidelines, and policy documents. In response to identified global research priorities, the evidence based first looked at implementation of hepatitis B birth dose vaccination and global, regional, national, and sub-national action plans.